P16 Immunoreactivity Is an Independent Predictor of Tumor Progression in Minimally Invasive Urothelial Bladder Carcinoma

According to our data, there is a significant correlation between loss of p16 expression and tumor progression in patients with minimally-invasive bladder cancer. Immunohistochemical p16 staining may therefore represent a useful tool of providing additional information on the clinical outcome of these patients.